tbuckley/cabot-search huggingface dataset:
Unexplained arterial embolism in patients less than 55 years of age: Role of primary cardiac tumors Birke Schneider, Eckart Schlemminger, Michael La�, Mathias Vierbuchen. St�dt. Krankenhaus S�d, L�beck, Germany, Allg. Krankenhaus St. Georg, Hamburg, Germany
Journal: Journal of the American College of Cardiology (2001)
Dietary practices of Asian diabetics
Authors: Graham Douglas, Lilian Teasdale
Journal: BMJ (1986)

Dietary practices of Asian diabeticsIn the legend to the table in the article "Dietary practices of Asian diabetics" (18 January, p 171) "unsaturated oil" should have read "unsaturated margarine."Relation between cause ofinjury and risks ofmultiple injuries and intracranial haematoma
P16.10 * DIAGNOSIS OF PSEUDOPROGRESSION IN PATIENTS WITH GLIOBLASTOMA USING AMINO ACID PET
Authors: N. Galldiks, V. Dunkl, G. Stoffels, M. Hutterer, M. Rapp, S. Kebir, R. Goldbrunner, M. I. Ruge, M. Schmidt, K. Langen
Journal: Neuro-Oncology (2014)

BACKGROUND: The follow-up of glioblastoma patients may be difficult with conventional MRI since reactive blood-brain barrier alterations with contrast enhancement can mimick tumor progression (“pseudoprogression”), especially early after completion of radiochemotherapy. PATIENTS AND METHODS: Twenty-six glioblastoma patients with newly appearance or an increase of enhancing lesions (>25%) on standard MRI with gadolinium-based contrast agents within the first 12 weeks after completion of radiochemotherapy with concomitant temozolomide (median time, 7 weeks) were additionally examined by amino acid PET using O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) (n = 22) or 11C-methyl-L-methionine (11C-MET) (n = 4). Median duration between MR and amino acid PET imaging was 7 d. Maximum and mean tumor/brain ratios (TBRmax, TBRmean) of 18F-FET and 11C-MET uptake were determined. Furthermore, 18F-FET uptake kinetic parameters (i.e., time-to-peak and patterns of the time-activity curves (TAC)) were evaluated. The presence of pseudoprogression/early tumor progression was based on the clinical course (progression-free survival (PFS) >/≤ 6 mo) and/or histopathological findings. Imaging results were also related to overall survival (OS). RESULTS: Pseudoprogression was confirmed in 14 of 26 patients. TBRmax and TBRmean of 18F-FET/11C-MET uptake were significantly higher in patients with early tumor progression (n = 12) than in patients with pseudoprogression (TBRmax, 3.6 ± 0.8 vs. 2.4 ± 0.4; TBRmean, 2.5 ± 0.3 vs. 1.8 ± 0.2; both P < 0.001). Furthermore, patterns of TAC were significantly different in both groups (P = 0.04) and presence of MGMT promoter methylation was significantly higher in patients with pseudoprogression (P = 0.02). Receiver-operating-characteristic analysis yielded a TBRmax of 2.9 as an optimal cut-off to identify early tumor progression (sensitivity, 92%; specificity, 93%; accuracy, 92%; area under the curve, 0.96 ± 0.04; P < 0.001). Univariate survival analyses revealed that a TBRmax < 2.9 predicted both a significantly longer PFS (median PFS, 21 vs. 5 months; P < 0.001) and OS (median OS, 33 vs. 12 months; P = 0.007). CONCLUSION: Amino acid PET contributes significantly in diagnosing pseudoprogression.
Errors in Table and Text in: Prevalence of and Factors Associated With Persistent Pain Following Breast Cancer Surgery
Authors: Becca Levy, Martin Slade, Terrence Murphy, Thomas Gill, Slade Levy, Gill Murphy
Journal: JAMA (2012)

the age-stereotype groupϫtime interaction (␤=Ϫ0.0004[95% CI, Ϫ0.0006 to Ϫ0.0002]; P=.001) showed that the positive age-stereotype group had a significantly slower rate of ADL decline.Comment.Older persons with positive age stereotypes were 44% more likely to fully recover from severe disability than those with negative age stereotypes.The study was limited by recruitment from 1 community; however, its demography is similar to the US population, except for an underrepresentation of black participants.Further research is needed to determine whether interventions to promote positive age stereotypes could extend independent living in later life.
Biomedical ethics
Authors: L. Walters
Journal: JAMA (1982)

In 1981 the human embryo and fetus were central figures in bioethical discussions. New diagnostic and therapeutic techniques made the human fetus seem more like a distinguishable patient, especially during the second and third trimesters of pregnancy. Within the legislative arena, the question of abortion was vigorously debated in hearings before the US Congress. Two distinct approaches to the abortion question emerged—one based on a proposed statute, the other based on a proposed constitutional amendment—and the issue of abortion seemed headed for a congressional showdown in 1982. At year's end the first successful birth in the United States following in vitro fertilization and embryo transfer was reported by a clinic in Norfolk, Va. <h3>The Fetus as Patient</h3> New techniques for prenatal diagnosis—for example, ultrasonography, amniocentesis, and fetoscopy—provide early information about the clinical status of the fetus to both prospective parents and physicians. This information then constitutes the basis for various
Book: Flu
Authors: C. Martyn
Journal: BMJ (2000)

Gina Kolata Macmillan, £12.99, pp 400 ISBN 0 333 75105 1 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> If you think negative strand RNA viruses are giving us a bad time at the moment, read this book to recalibrate your perspective. It's about the influenza pandemic that gripped the world in 1918,killing more people in a few months than the armies of the first world war slaughtered on the battlefields of Flanders, northern France, and Gallipoli in four years. An estimated 25% of the world's population suffered a clinical … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
American Rheumatism Association: Proceedings of Annual Meeting, 1954
Journal: Annals of the Rheumatic Diseases (1954)

Since the end of the second world war, the American Rheumatism Association has experienced a phenomenal growth in membership, in total number as well as in those participating actively at meetings.The physical size of the programme has grown, and it seems fair to say, without false pride, that the character of the programme has improved remarkably.The papers presented show more interest in basic problems and an increasingly careful evaluation of therapeutic agents.Young men have entered the field in larger numbers than could have been anticipated in the past, and in many instances, through support from the United States Public Health Service or the Arthritis and Rheumatism Foundation, they have provided themselves with a solid background of basic science upon which to build in the future.This we may regard as sound achievement.On the other side of the ledger, we have only to look at one of our major problemsrheumatoid arthritis-to realize that we have yet a long way to go.We continue to be in the dark concerning the origin and progression of this disease, and its course may only be predicted on a statistical basis, although our knowledge of the tissues and the changes induced by the disease has unquestionably advanced.There is, I believe, reason for this dichotomy.It is obvious that no one has a clear-cut * There were also panel discussions on "Hormones in Rheumatic Disease" (Moderator: R. H. Freyberg) and "Rehabilitation of the Arthritic Patient" (Moderator: E. W. Lowman).physiatrist, as well as the endocrinologist and medical orthopaedist.This makes for a compleat family physician.In the clinical investigation of the rheumatic diseases, each of these disciplines may 344 copyright.
Fewer Opioids, More Exercise for Severe Joint Pain From Arthritis
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROPRIETARY REMEDIES AND THE DERMATOLOGIST.
Journal: JAMA Dermatology (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Growth factor-dependent initiation of DNA replication in nuclei isolated from an interleukin 3-dependent murine myeloid cell line
Journal: Journal of Clinical Investigation (1990)

Column 2, paragraph 2, under "DNA replication assay" the additional line is "The replication mixture additionally contained 2.8 mM MgCl2 and 5 mM KH2PO4 in the final volume of 80 ,l."
Laser treatment of congenital melanocytic naevi: a systematic review
Authors: C.A.M. Eggen, J.E. Lommerts, E.J. van Zuuren, J. Limpens, S.G.M.A. Pasmans, A. Wolkerstorfer
Journal: British Journal of Dermatology (2018)

Most people have a few brown spots on their skin known as melanocytic naevi or moles. Moles are harmless but can occasionally transform into a potentially lethal tumour called malignant melanoma. Congenital melanocytic nevi (CMN) are ones that are present at birth or develop in the first few weeks of life. Congenital nevi, in particular those that are large in size and on visible areas of skin, can be a great burden when people are unhappy with how they look. Moreover, there is an increased risk of developing malignant melanoma in patients with CMN, especially in the larger CMN. The lifetime risk of malignant melanoma in patients with CMN is thought to be about 0.7% to 2.9%. Surgically removing (excision of) the CMN to decrease the risk of melanoma has been a common treatment, however, this has not been proven to reduce the risk of melanoma. CMN can be too large to completely remove with excision, and excision can cause scarring. Therefore, in more recent years, other treatments have been explored, including the use of lasers to remove the CMN. This option is controversial, mainly because of the lack of evidence on efficacy, and safety concerns. Some state that lasers may reduce the risk of malignancy by decreasing the melanocytic mass while others are concerned about the potential cancer‐causing risk of laser damage. The objective of this study from the Netherlands was to review the efficacy and safety of different laser types used for CMN. The researchers found that a great variety of laser devices and combinations of lasers have been used for treatment of congenital nevi. There is very low quality evidence that laser therapy in CMN is effective and safe in the short term, however there were high incidences of scarring, repigmentation (colour coming back) and complications. More high quality studies are required in order to really answer the question regarding efficacy and safety of laser treatment in CMN.
Pathology
Authors: A. E. Rodin
Journal: JAMA (1973)

The "concise synopsis" format of medical textbooks has increased in popularity in the past decade, especially for basic science fields that have had reduction in number of hours of student contact and, presumably, in content. These have varied from printed lecture notes to condensed treatises. Two new pathology books exemplify the trends and the problems. Tighe's<i>Pathology</i>is a mere 319 pages with no illustrations and few tables. Although Anderson and Scotti's<i>Synopsis of Pathology</i>is 1,076 pages of the same size, it does not have three times the content, as the print is larger and there are 430 illustrations and numerous tables. Both texts follow the traditional organization of the subject, but from this point on they diverge drastically. Tighe's<i>Pathology</i>suffers from inconsistent pattern, inappropriate emphasis, and confusion of purpose. The same amount of space is given to both histiocytosis X and diabetes, with no mention of juvenile
Effect of Pressor Amines on Experimental Intracardiac Shunts and Valvular Regurgitation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de S. A. Giday et al., pp. 525
Journal: Endoscopy (2007)

See also: The utility of contrast-enhanced endoscopic ultrasound in monitoring ethanol-induced pancreatic tissue ablation: a pilot study in a porcine modelEndoscopy 2007; 39(06): 525-529DOI: 10.1055/s-2007-966391
TOXICS.
Authors: WM. F. BARCLAY
Journal: JAMA (1895)

A poison is a substance, which when taken into the system is either absorbed or by its thermal action on the parts with which it is in contact produces deleterious effects. It may seem strange that almost all toxics are innocent, until they reach the circulation of the blood. Their slow or rapid absorption largely determines their deleterious effects upon the system. In our observations we are reminded from time to time of the idiosyncrasies of individuals and we seldom inquire into the causes of these peculiar conditions. It is generally attributed to a perversion of the nervous system, but in truth is caused by a rapid absorption of the poison and is modified by the power of resistance inherent in the individual. Hereditary predispositions and peculiar cachexias in persons are dissimilar conditions, and are in no sense identical. Heredity has not been defined satisfactorily, but the conditions of progenitors
Principles of Surgery.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACTR-52. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY – A SAFETY ANALYSIS
Authors: Adrian Kinzel, Gitit Lavy-Shahaf, Eilon Kirson
Journal: Neuro-Oncology (2018)

INTRODUCTION: TTFields are low intensity, intermediate frequency, alternating electric fields. The significant overall and progression-free survival benefit, shown in the EF-14 phase 3 study was seen in all patient-subgroups, independent of e.g. MGMT-promotor methylation-status or age. TTFields were not associated with additional systemic toxicity. At recurrence, patients were allowed to continue TTFields with second-line therapies. Here, we analyzed the safety data of TTFields + lomustine (CCNU) to evaluate safety and feasibility of this combination. Patients in the EF-14 trial received TTFields until second progression, or for 24 months. Change in chemotherapy regimen was allowed after tumor progression. We compared the patients who received lomustine as second-line chemotherapy in combination with TTFields (n=134) to the patients who received lomustine as monotherapy after first progression (n=39). We compared baseline characteristics and the adverse event profile between the groups. Baseline characteristics were well balanced except for less female patients in the lomustine only group (7.7% vs. 22.4%). Median age in the TTFields/lomustine group was 55.5 years (29–83) compared to 50.0 years (19–71) for lomustine alone. The addition of TTFields to lomustine therapy was not associated with any significant increase in systemic adverse events compared to lomustine therapy alone (number of patients with 1 SAE 30 % vs. 31 %) and the distribution, severity and overall incidence of adverse events were not statistically different in patients in the two treatment groups. CONCLUSION: The data show that the combination of TTFields and lomustine is safe and feasible. This analysis emphasizes again the strong safety profile of TTFields and the high potential of combining TTFields with other modalities. This data is especially important in light of the recently presented, promising data from a small randomized trial that tested the combination of lomustine + TMZ in newly diagnosed (MGMT promotor-methylated only) glioblastoma patients.
Part-time Medical Officers, H.M. Prisons
Authors: J. H. Swan
Journal: BMJ (1970)

MDILJOURNALany later sets (that is, to hazards which ter- minate in abortions), we can safely assume that the observed downward gradient was not as steep as the true gradient.In short, tumours which grow relatively slowly are bound to have relatively late onset dates and dates of death, and the reverse must be true of fast growing tumours.It is also very likely that the different rates of growth are determined by the affected tissues.But one of the purposes of our recent article was to show that prob- ably all juvenile cancers are initiated before birth.Another was to show that the interval between initiation and onset for a given type of cancer is relatively constant and may exceed ten years.-Weare, etc.,
Shigella sonnei Outbreak Associated With Contaminated Drinking Water— Island Park, Idaho, August 1995
Journal: JAMA (1996)

On August 20, 1995, the District 7 Health Department requested the Idaho Department of Health to assist in investigating reports of diarrheal illness among visitors to a resort in Island Park in eastern Idaho; Shigella sonnei had been isolated from stool cultures of some cases. This report summarizes the findings of the investigation, which implicated contaminated drinking water as the cause of the outbreak.
Cardiac dimension changes with endurance training. Indications of a genotype dependency
Authors: F. Landry
Journal: JAMA (1985)

We studied the sensitivity of cardiac structures to endurance training. To evaluate variability in adaptation, 20 sedentary subjects and ten pairs of monozygotic twins were submitted to a 20-week endurance training program. Maximal oxygen uptake increased significantly in both groups: 11 mL O<sub>2</sub>/kg/min<sup>-1</sup>or 30% in the sedentary group and 6 mL O<sub>2</sub>/kg/min<sup>-1</sup>or 13% in the monozygotic twins. Statistically significant increases in left ventricular diameter, posterior wall and septal thicknesses, as well as left ventricular end-diastolic volume and left ventricular mass were observed in the sedentary subjects, but not in the monozygotic twins. We could demonstrate that after training, twin pairs differed more from each other than at the start. Concomitantly, within-pair resemblance was greater after training than before. Results indicate that cardiac dimensions are amenable to significant modifications under controlled endurance training conditions and furthermore that the extent and variability of the response of cardiac structures to training are perhaps genotype dependent. (<i>JAMA</i>1985;254:77-80)
Correction: History and Future of Treatment of Hypothyroidism
Journal: Annals of Internal Medicine (2016)

There is an error in a recent article. The last sentence of the section titled "L-Thyroxine Monotherapy Fails to Restore All Markers of Hypothyroidism" should read "new technology is needed to allow for steady delivery of L-triiodothyronine" (it currently reads "… for steady delivery of L-thyroxine").This has been corrected in the online version.
Evaluation of parathyroid gland lesions
Authors: D. R. Dufour
Journal: JAMA (1982)

<h3>In Reply.—</h3> Dr Dufour's letter underscores the difficulties that endocrine pathologists and surgeons face when they attempt to establish a clear differentiation between hyperplasia and adenoma of the parathyroid glands. It is necessary to recognize that parathyroid adenomas, like their counterparts in the adrenal, pituitary, and thyroid glands, develop from a background of cellular hyperplasia that can then progress to nodular hyperplasia, to adenoma formation, and, on rare occasions, to frank carcinomatous dedifferentiation.<sup>1,2</sup>Given this sequence of events, it follows that there will be instances where combinations of hyperplasia, nodular hyperplasia, single adenoma, or "double adenomas" coexist in the same patient and, at times, within the same parathyroid gland. Unfortunately, controversy over the classification of parathyroid histopathology has not resolved the endocrine surgeon's dilemma at the time of surgery. Only then can the extent of the disease, including the number of glands involved, and whether a particular gland is